Efficacy and Safety of the Enterosorbent Silicolgel in Irritable Bowel Syndrome, IBS‐D and IBS‐M : A Randomized, Double‐Blind, Placebo‐Controlled, Multi‐Center Trial
Neurogastroenterology & Motility · 2025-12 · 37 (12)
DOI: 10.1111/nmo.70118 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 25.07.2025. Verfasst von O Kuzminska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chernivtsi Hospital of Emergency Medical Care, Chernivtsi, Ukraine. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FW Medical Ltd and Delta Medical LLC.
Abstract (Originalsprache)
Background
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder significantly reducing quality of life. Silicolgel, a colloidal silicic acid enterosorbent, acts locally in the gut. This double‐blind, placebo‐controlled trial investigated its safety and efficacy in IBS‐D and IBS‐M, subtypes affecting over 60% of IBS sufferers.
Methods
After 2 weeks of screening, patients were randomized into 4 weeks of treatment, followed by a no‐medication phase to assess return of symptoms. Patients recorded bowel habits, abdominal pain, QoL, and global symptoms using weekly questionnaires and daily diaries. Primary outcome was a ≥ 50 point reduction in IBS Severity Scoring System (IBS SSS).
Results
From 139 adults with ROME IV IBS‐D or IBS‐M, 120 were randomized and all completed screening and treatment phases (silicolgel n = 60, placebo n = 60). After 4 weeks' treatment: 91.67% (ITT) achieved the primary outcome in the silicolgel group versus 20.00% for placebo (relative risk (RR) = 4.58, 95% CI 2.74–7.65, p < 0.001). Mean IBS SSS for silicolgel reduced to 92.75 [62.68], −162.87 versus 257.58 [74.94] +3.17 for the placebo group ( U = 210.5, r = 0.76, p < 0.001). Silicolgel also improved bowel habit, abdominal pain, distension, flatulence, and QoL. IBS‐D and IBS‐M patients showed the same improvements. Adverse events were similar in both groups, with no serious events attributable to silicolgel or placebo. Onset of action was rapid; after 2 weeks, 85.0% on silicolgel achieved the primary outcome versus 11.7% on placebo (significant difference).
Conclusion
Silicolgel is safe and effective in IBS‐D and IBS‐M, providing an alternative to the limited treatments currently available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chernivtsi Hospital of Emergency Medical Care, Chernivtsi, Ukraine.
- Head of the Gastroenterology Department, TOV "GASTROTSENTR", Kyiv, Ukraine.
- Medical Writer, Verum Clinical Study LLC, Kyiv, Ukraine.
- FW Medical Ltd, Glasgow, UK.
ORCID-Profile: Chris G Hatton
Förderung
- FW Medical Ltd and Delta Medical LLC
Zitieren
APA
Kuzminska, O., Vitkovska, B., Kuvaiskov, Y., & Hatton, C. G. (2025). Efficacy and Safety of the Enterosorbent Silicolgel in Irritable Bowel Syndrome, IBS‐D and IBS‐M : A Randomized, Double‐Blind, Placebo‐Controlled, Multi‐Center Trial. Neurogastroenterology & Motility, 37(12). https://doi.org/10.1111/nmo.70118
Vancouver
Kuzminska O, Vitkovska B, Kuvaiskov Y, Hatton CG. Efficacy and Safety of the Enterosorbent Silicolgel in Irritable Bowel Syndrome, IBS‐D and IBS‐M : A Randomized, Double‐Blind, Placebo‐Controlled, Multi‐Center Trial. Neurogastroenterology & Motility. 2025;37(12). doi:10.1111/nmo.70118
BibTeX
@article{Kuzminska2025,
author = {Kuzminska, O and Vitkovska, B and Kuvaiskov, Yurii and Hatton, Chris G},
title = {Efficacy and Safety of the Enterosorbent Silicolgel in Irritable Bowel Syndrome, IBS‐D and IBS‐M : A Randomized, Double‐Blind, Placebo‐Controlled, Multi‐Center Trial},
journal = {Neurogastroenterology & Motility},
year = {2025},
volume = {37},
number = {12},
doi = {10.1111/nmo.70118}
}
EUVIMED